Targeted Oncology

Patient Survey Sheds Light on Critical Communication Gaps in NMIBC Care

A significant communication gap exists between NMIBC patients and providers, with only 18% having regular discussions about ...
Healio

FDA approves Keytruda plus Padcev for muscle invasive bladder cancer

The FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph in combination with enfortumab vedotin-ejfv ...

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortuma…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...
TipRanks on MSN

Merck: FDA approves Keytruda, Keytruda Qlex in combo with Padcev

Merck (MRK) announced that the U.S. FDA has approved Keytruda and Keytruda Qlex in combination with Padcev as neoadjuvant treatment and then ...

U.S. FDA Approves PADCEV(R) plus Keytruda(R) for Certain Patients with Bladder Cancer

(TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (R) (enfortumab vedotin-ejfv), a Nectin-4 directed ...
Le Lézard

U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer

Pfizer Inc. and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin ...
CURE

FDA Approves Keytruda and Padcev for Muscle Invasive Bladder Cancer

Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive ...
Targeted Oncology

FDA Approves Enfortumab Vedotin Plus Pembrolizumab for MIBC

The FDA approved enfortumab vedotin and pembrolizumab for MIBC, following a priority review of their sBLA for neoadjuvant and ...